Immune checkpoint inhibitors (ICI), targeting the PD1/PD-L1 axis has shown their efficacy in lung cancer but only in a restricted population of patients, thus it is mandatory to identify biomarkers predicting the clinical benefit. In this article we will describe and analyzed biomarkers already published, from protein, to RNA and at last DNA markers, discussing each markers feasibility and interest. In the future, combined analysis of several markers will probably be proposed, particularly with the increasing complexity of therapy schema with molecules association.
Keywords: Biomarkers; Biomarqueurs; Cancer broncho-pulmonaire; Immune checkpoint inhibitors; Immunotherapy; Immunothérapie; Inhibiteurs des immune checkpoint; Lung cancer.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.